Another similar clinical case was reported by Wondergem et al., who noticed increased PSMA uptake in lymph node metastases after initiation of enzalutamide treatment, whereas lymph node volume and PSA decreased over time [34]. Here, FOLH1 is linked to metastatic malignant neoplasm in the lymph nodes.